G protein-coupled receptor GPR49 has been reported to be expressed in brain, skeletal muscle, placenta, and spinal cord. ESTs have been isolated from normal human brain (amygdala), embryo, and placenta libraries and from human germ cell, uterus, and brain libraries. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
follicle expressed hormone; G protein-coupled receptor 49; G-protein coupled receptor 49; G-protein coupled receptor 67; G-protein coupled receptor HG38; leucine-rich repeat containing G protein-coupled receptor 5; leucine-rich repeat-containing G protein-coupled receptor 5; Leucine-rich repeat-containing G-protein coupled receptor 5; orphan G protein-coupled receptor HG38; Orphan G-protein coupled receptor FEX